An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia

Published:2015-04-09 Issue:15 Volume:125 Page:2336-2343
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Sharman Jeff¹,Hawkins Michael²,Kolibaba Kathryn³,Boxer Michael⁴,Klein Leonard⁵,Wu Meihua²,Hu Jing²,Abella Steve²,Yasenchak Chris¹

Affiliation:

1. Willamette Valley Cancer Institute and Research Center/US Oncology Research, Springfield, OR;

2. Gilead Sciences, Inc., Foster City, CA;

3. Compass Oncology/US Oncology Research, Vancouver, WA;

4. Arizona Oncology, Tucson, AZ; and

5. Lutheran General Hospital, Niles, IL

Abstract

Key Points Entospletinib is a selective inhibitor of spleen tyrosine kinase, which is implicated in the pathobiology of B-cell lymphoid malignancies. Entospletinib shows clinical activity in subjects with relapsed or refractory CLL with acceptable toxicity.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/15/2336/1384310/2336.pdf

Reference20 articles.

1. Molecular mechanism of the Syk activation switch.;Tsang;J Biol Chem,2008

2. Structural basis for Syk tyrosine kinase ubiquity in signal transduction pathways revealed by the crystal structure of its regulatory SH2 domains bound to a dually phosphorylated ITAM peptide.;Fütterer;J Mol Biol,1998

3. Thermodynamic study of the binding of the tandem-SH2 domain of the Syk kinase to a dually phosphorylated ITAM peptide: evidence for two conformers.;Grucza;Biochemistry,1999

4. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.;Gobessi;Leukemia,2009

5. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor.;Chiorazzi;Annu Rev Immunol,2003

Cited by 157 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pyrazine-based small molecule kinase inhibitors: clinical applications and patent review (2019–2023);Future Medicinal Chemistry;2024-08-27

2. Spleen tyrosine kinase (SYK): an emerging target for the assemblage of small molecule antitumor agents;Expert Opinion on Investigational Drugs;2024-08-11

3. The Syk Inhibitor Entospletinib Abolishes Dermal–Epidermal Separation in a Fully Human Ex Vivo Model of Bullous Pemphigoid;Journal of Investigative Dermatology;2024-08

4. Development of SYK NanoBRET cellular target engagement assays for gain–of–function variants;Frontiers in Chemical Biology;2024-07-29

5. Development of SYK NanoBRET Cellular Target Engagement Assays for Gain–of–Function Variants;2024-06-13